Ashton J. Friend
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ashton J. Friend has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Allan V. Kalueff
Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia
10 shared publications Tamara G. Amstislavskaya
Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk, Russia; The International Zebrafish Neuroscience Research Consortium (ZNRC), Slidell, LA, USA
10 shared publicationsAndrey D. Volgin
Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia; Translational Biopsychiatry Laboratory, Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk, Russia
7 shared publicationsWandong Bao
School of Pharmacy, Southwest University, Chongqing, China; The International Zebrafish Neuroscience Research Consortium (ZNRC), Slidell, LA, USA
7 shared publicationsKonstantin A. Demin
Institute of Experimental Medicine, Almazov National Medical Research Centre, Ministry of Healthcare of Russian Federation, St. Petersburg, Russia; Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia
6 shared publications- Murilo Sander de Abreu
Graduate Program in Health Sciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil
6 shared publications
Latest Publications
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 2
Nicotinamide Adenine Dinucleotide (NAD) Attenuates the Rate-Decreasing Effects of Oxycodone Withdrawal in Rats with No Apparent Abuse Liability
ID 56040 Poster Board 2 Background: Two current treatments for opioid use disorder (OUD) are the chronic administration of buprenorphine (partial opioid receptor agonist) or methadone (full opioid receptor agonist), as both of these agonists can alleviate withdrawal symptoms. However, neither of these drugs transition individuals with OUD to abstinence, and they both have an abuse liability. We examined whether the intravenous administration of the small molecule NAD+ could effectively attenuate withdrawal and transition individuals to abstinence (Experiment 1) while also having no abuse liability (Experiment 2). Methods: In Experiment 1, prior to establishing oxycodone dependence, seven Long-Evans rats (4 male and 3 female) were trained to lever press under a fixed-ratio 30 schedule for food reinforcers. When responding stabilized, subjects were administered an increasing chronic regimen of oxycodone (i.e., 3.2 mg/kg of oxycodone once daily, 3.2 mg/kg twice daily, and 10-18 mg/kg twice daily) until both spontaneous and precipitated withdrawal were reflected by disruptions in overall response rate (responses/second) and pre-ratio pausing (seconds). Precipitated withdrawal was demonstrated by administering increasing cumulative doses of naltrexone i.p. (0.32-3.2 mg/kg). After disruption of behavioral responding (withdrawal) was demonstrated consistently, indicating dependence, surgery was performed to implant a catheter and port. Twenty-four hours following catheterization, the chronic oxycodone regimen was restarted for the recovery period from surgery and for reestablishing responding under the operant schedule. When responding stabilized, the chronic regimen of oxycodone was permanently discontinued, and subjects were infused i.v. with either saline or 180 mg/kg of NAD+ each night for 10 hours per day for 10 consecutive days. Subjects responded under the operant task every afternoon during the 10 days to assess the disruptions in behavior. In Experiment 2, four male Sprague-Dawley rats were trained to respond under a fixed-ratio 10 schedule of oxycodone reinforcement after catheterization. During these sessions, overall response rate and pre-ratio pausing (PRP) were recorded. After self administration was established for an oxycodone training dose of 0.032 mg/kg/infusion, saline or NAD+ (1.57 or 3.2 mg/kg/infusion) was substituted for oxycodone until one of three criteria were met. Results: In Experiment 1, precipitated and spontaneous withdrawal from oxycodone decreased response rate and increased PRP. When oxycodone was permanently discontinued, subjects given 10 days of i.v. NAD+ recovered their pre-chronic baseline of responding after 2 days of oxycodone cessation, while the saline group recovered their pre-chronic baseline after 4 days. PRP was also restored more quickly in the NAD+ group than the saline group. In Experiment 2, the mean number of oxycodone infusions was 23.6 ± 7.6, whereas the number of infusions was markedly reduced when saline (6.7) or NAD+ (6.2 ± 3.7 and 1.6 ± 0.89) was substituted for oxycodone. Conclusion: In our rodent model of opioid-dependence, i.v. NAD+ infusions reduced the duration and magnitude of the rate-decreasing effects of oxycodone, which were a direct reflection of withdrawal. Of the NAD+ infusion doses tested, neither dose substituted for oxycodone and produced levels of responding closer to those for saline. These results reveal that NAD+ may have promising potential as a treatment for dependence.
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 2
Open AccessNicotinamide Adenine Dinucleotide (NAD) Attenuates the Rate-Decreasing Effects of Oxycodone Withdrawal in Rats with No Apparent Abuse Liability
ID 56040 Poster Board 2 Background: Two current treatments for opioid use disorder (OUD) are the chronic administration of buprenorphine (partial opioid receptor agonist) or methadone (full opioid receptor agonist), as both of these agonists can alleviate withdrawal symptoms. However, neither of these drugs transition individuals with OUD to abstinence, and they both have an abuse liability. We examined whether the intravenous administration of the small molecule NAD+ could effectively attenuate withdrawal and transition individuals to abstinence (Experiment 1) while also having no abuse liability (Experiment 2). Methods: In Experiment 1, prior to establishing oxycodone dependence, seven Long-Evans rats (4 male and 3 female) were trained to lever press under a fixed-ratio 30 schedule for food reinforcers. When responding stabilized, subjects were administered an increasing chronic regimen of oxycodone (i.e., 3.2 mg/kg of oxycodone once daily, 3.2 mg/kg twice daily, and 10-18 mg/kg twice daily) until both spontaneous and precipitated withdrawal were reflected by disruptions in overall response rate (responses/second) and pre-ratio pausing (seconds). Precipitated withdrawal was demonstrated by administering increasing cumulative doses of naltrexone i.p. (0.32-3.2 mg/kg). After disruption of behavioral responding (withdrawal) was demonstrated consistently, indicating dependence, surgery was performed to implant a catheter and port. Twenty-four hours following catheterization, the chronic oxycodone regimen was restarted for the recovery period from surgery and for reestablishing responding under the operant schedule. When responding stabilized, the chronic regimen of oxycodone was permanently discontinued, and subjects were infused i.v. with either saline or 180 mg/kg of NAD+ each night for 10 hours per day for 10 consecutive days. Subjects responded under the operant task every afternoon during the 10 days to assess the disruptions in behavior. In Experiment 2, four male Sprague-Dawley rats were trained to respond under a fixed-ratio 10 schedule of oxycodone reinforcement after catheterization. During these sessions, overall response rate and pre-ratio pausing (PRP) were recorded. After self administration was established for an oxycodone training dose of 0.032 mg/kg/infusion, saline or NAD+ (1.57 or 3.2 mg/kg/infusion) was substituted for oxycodone until one of three criteria were met. Results: In Experiment 1, precipitated and spontaneous withdrawal from oxycodone decreased response rate and increased PRP. When oxycodone was permanently discontinued, subjects given 10 days of i.v. NAD+ recovered their pre-chronic baseline of responding after 2 days of oxycodone cessation, while the saline group recovered their pre-chronic baseline after 4 days. PRP was also restored more quickly in the NAD+ group than the saline group. In Experiment 2, the mean number of oxycodone infusions was 23.6 ± 7.6, whereas the number of infusions was markedly reduced when saline (6.7) or NAD+ (6.2 ± 3.7 and 1.6 ± 0.89) was substituted for oxycodone. Conclusion: In our rodent model of opioid-dependence, i.v. NAD+ infusions reduced the duration and magnitude of the rate-decreasing effects of oxycodone, which were a direct reflection of withdrawal. Of the NAD+ infusion doses tested, neither dose substituted for oxycodone and produced levels of responding closer to those for saline. These results reveal that NAD+ may have promising potential as a treatment for dependence.
- 1 October 2019
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 105, 126-133
Developing zebrafish experimental animal models relevant to schizophrenia
- 1 October 2019
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 105, 126-133
Developing zebrafish experimental animal models relevant to schizophrenia
- 1 April 2019
- Published by Elsevier in Neuroscience
- Vol. 404, 218-232
Opioid Neurobiology, Neurogenetics and Neuropharmacology in Zebrafish
- 1 April 2019
- Published by Elsevier in Neuroscience
- Vol. 404, 218-232
Opioid Neurobiology, Neurogenetics and Neuropharmacology in Zebrafish
- 1 January 2019
- Published by Elsevier in Behavioural Processes
- Vol. 158, 200-210
Understanding zebrafish aggressive behavior
- 1 January 2019
- Published by Elsevier in Behavioural Processes
- Vol. 158, 200-210
Understanding zebrafish aggressive behavior
- 1 November 2018
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 94, 16-22
Zebrafish models: do we have valid paradigms for depression?
- 1 November 2018
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 94, 16-22
Zebrafish models: do we have valid paradigms for depression?
- Open Access
- 15 October 2018
- Published by Wiley in Journal of Neuroscience Research
- Vol. 97 (4) , 402-413
Zebrafish models for personalized psychiatry: Insights from individual, strain and sex differences, and modeling gene x environment interactions
Currently becoming widely recognized, personalized psychiatry focuses on unique physiological and genetic profiles of patients to best tailor their therapy. However, the role of individual differences, as well as genetic and environmental factors, in human psychiatric disorders remains poorly understood. Animal experimental models are a valuable tool to improve our understanding of disease pathophysiology and its molecular mechanisms. Due to high reproduction capability, fully sequenced genome, easy gene editing, and high genetic and physiological homology with humans, zebrafish (Danio rerio) are emerging as a novel powerful model in biomedicine. Mounting evidence supports zebrafish as a useful model organism in CNS research. Robustly expressed in these fish, individual, strain, and sex differences shape their CNS responses to genetic, environmental, and pharmacological manipulations. Here, we discuss zebrafish as a promising complementary translational tool to further advance patient‐centered personalized psychiatry.
- 15 October 2018
- Published by Wiley in Journal of Neuroscience Research
- Vol. 97 (4) , 402-413
Open AccessZebrafish models for personalized psychiatry: Insights from individual, strain and sex differences, and modeling gene x environment interactions
Currently becoming widely recognized, personalized psychiatry focuses on unique physiological and genetic profiles of patients to best tailor their therapy. However, the role of individual differences, as well as genetic and environmental factors, in human psychiatric disorders remains poorly understood. Animal experimental models are a valuable tool to improve our understanding of disease pathophysiology and its molecular mechanisms. Due to high reproduction capability, fully sequenced genome, easy gene editing, and high genetic and physiological homology with humans, zebrafish (Danio rerio) are emerging as a novel powerful model in biomedicine. Mounting evidence supports zebrafish as a useful model organism in CNS research. Robustly expressed in these fish, individual, strain, and sex differences shape their CNS responses to genetic, environmental, and pharmacological manipulations. Here, we discuss zebrafish as a promising complementary translational tool to further advance patient‐centered personalized psychiatry.
- 1 October 2018
- Published by SAGE Publications in Zebrafish
- Vol. 15 (5) , 425-432
Understanding the Role of Environmental Enrichment in Zebrafish Neurobehavioral Models
Environmental stimuli are critical in preclinical research that utilizes laboratory animals to model human brain disorders. The main goal of environmental enrichment (EE) is to provide laboratory animals with better choice of activity and greater control over social and spatial stressors. Thus, in addition to being a useful experimental tool, EE becomes an important strategy for increasing the validity and reproducibility of preclinical data. Although zebrafish ( Danio rerio ) is rapidly becoming a promising new organism for neuroscience research, the role of EE in zebrafish central nervous system (CNS) models remains poorly understood. Here we discuss EE in preclinical studies using zebrafish and its influence on brain physiology and behavior. Improving our understanding of EE effects in this organism may enhance zebrafish data validity and reliability. Paralleling rodent EE data, mounting evidence suggests the growing importance of EE in zebrafish neurobehavioral models.
- 1 October 2018
- Published by SAGE Publications in Zebrafish
- Vol. 15 (5) , 425-432
Understanding the Role of Environmental Enrichment in Zebrafish Neurobehavioral Models
Environmental stimuli are critical in preclinical research that utilizes laboratory animals to model human brain disorders. The main goal of environmental enrichment (EE) is to provide laboratory animals with better choice of activity and greater control over social and spatial stressors. Thus, in addition to being a useful experimental tool, EE becomes an important strategy for increasing the validity and reproducibility of preclinical data. Although zebrafish ( Danio rerio ) is rapidly becoming a promising new organism for neuroscience research, the role of EE in zebrafish central nervous system (CNS) models remains poorly understood. Here we discuss EE in preclinical studies using zebrafish and its influence on brain physiology and behavior. Improving our understanding of EE effects in this organism may enhance zebrafish data validity and reliability. Paralleling rodent EE data, mounting evidence suggests the growing importance of EE in zebrafish neurobehavioral models.
- 1 August 2018
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 86, 301-312
Zebrafish models relevant to studying central opioid and endocannabinoid systems
- 1 August 2018
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 86, 301-312
Zebrafish models relevant to studying central opioid and endocannabinoid systems
- 1 June 2018
- Published by Elsevier in European Journal of Pharmacology
- Vol. 829, 129-140
Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models
- 1 June 2018
- Published by Elsevier in European Journal of Pharmacology
- Vol. 829, 129-140
Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models
- 1 June 2018
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 92, 1-12
Psychoneuroimmunology and immunopsychiatry of zebrafish
- 1 June 2018
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 92, 1-12
Psychoneuroimmunology and immunopsychiatry of zebrafish